GLP1R and type 2 diabetes mellitus: At present, the GLP-1 receptor agonists exendin-4 (Exenatide, Byetta®, Bydureon®) (44, 45), liraglutide (Victoza®) (46), albiglutide [Eperzan® (EU) Tanzeum® (US)] (47, 48), dulaglutide (TrulicityTM®) (49), lixisenatide (Lyxumia®, Adlyxin®) (50), semaglutide (Ozempic®, Rybelsus®) (51, 52), are approved to treat T2DM (53) (see Table 1).